151 related articles for article (PubMed ID: 19196511)
1. Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists.
Biju P; Taveras AG; Dwyer MP; Yu Y; Chao J; Hipkin RW; Fan X; Rindgen D; Fine J; Lundell D
Bioorg Med Chem Lett; 2009 Mar; 19(5):1431-3. PubMed ID: 19196511
[TBL] [Abstract][Full Text] [Related]
2. Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region.
Aki C; Chao J; Ferreira JA; Dwyer MP; Yu Y; Chao J; Merritt RJ; Lai G; Wu M; Hipkin RW; Fan X; Gonsiorek W; Fosseta J; Rindgen D; Fine J; Lundell D; Taveras AG; Biju P
Bioorg Med Chem Lett; 2009 Aug; 19(15):4446-9. PubMed ID: 19525110
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.
Dwyer MP; Yu Y; Chao J; Aki C; Chao J; Biju P; Girijavallabhan V; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; Rokosz LL; Kaiser B; Li G; Wang W; Stauffer T; Ozgur L; Baldwin J; Taveras AG
J Med Chem; 2006 Dec; 49(26):7603-6. PubMed ID: 17181143
[TBL] [Abstract][Full Text] [Related]
4. C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists.
Chao J; Taveras AG; Chao J; Aki C; Dwyer M; Yu Y; Purakkattle B; Rindgen D; Jakway J; Hipkin W; Fosetta J; Fan X; Lundell D; Fine J; Minnicozzi M; Phillips J; Merritt JR
Bioorg Med Chem Lett; 2007 Jul; 17(13):3778-83. PubMed ID: 17459706
[TBL] [Abstract][Full Text] [Related]
5. 3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists.
Biju P; Taveras A; Yu Y; Zheng J; Chao J; Rindgen D; Jakway J; Hipkin RW; Fossetta J; Fan X; Fine J; Qiu H; Merritt JR; Baldwin JJ
Bioorg Med Chem Lett; 2008 Jan; 18(1):228-31. PubMed ID: 18006311
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists.
Yu Y; Dwyer MP; Chao J; Aki C; Chao J; Purakkattle B; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Qiu H; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; He Z; Lai G; Wu M; Taveras A
Bioorg Med Chem Lett; 2008 Feb; 18(4):1318-22. PubMed ID: 18242983
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and structure-activity relationships of new disubstituted phenyl-containing 3,4-diamino-3-cyclobutene-1,2-diones as CXCR2 receptor antagonists.
Lai G; Merritt JR; He Z; Feng D; Chao J; Czarniecki MF; Rokosz LL; Stauffer TM; Rindgen D; Taveras AG
Bioorg Med Chem Lett; 2008 Mar; 18(6):1864-8. PubMed ID: 18304809
[TBL] [Abstract][Full Text] [Related]
9. N,N'-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors.
Nie H; Widdowson KL; Palovich MR; Fu W; Elliott JD; Bryan DL; Burman M; Schmidt DB; Foley JJ; Sarau HM; Busch-Petersen J
Bioorg Med Chem Lett; 2006 Nov; 16(21):5513-6. PubMed ID: 16934456
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent and orally bioavailable N,N'-diarylurea antagonists for the CXCR2 chemokine receptor.
Jin Q; Nie H; McCleland BW; Widdowson KL; Palovich MR; Elliott JD; Goodman RM; Burman M; Sarau HM; Ward KW; Nord M; Orr BM; Gorycki PD; Busch-Petersen J
Bioorg Med Chem Lett; 2004 Sep; 14(17):4375-8. PubMed ID: 15357956
[TBL] [Abstract][Full Text] [Related]
11. 3,4-Diamino-1,2,5-thiadiazole as potent and selective CXCR2 antagonists.
Biju P; Taveras AG; Yu Y; Zheng J; Hipkin RW; Fossetta J; Fan X; Fine J; Lundell D
Bioorg Med Chem Lett; 2009 Mar; 19(5):1434-7. PubMed ID: 19200721
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and structure-activity relationships of 3,4-diaminocyclobut-3-ene-1,2-dione CXCR2 antagonists.
Merritt JR; Rokosz LL; Nelson KH; Kaiser B; Wang W; Stauffer TM; Ozgur LE; Schilling A; Li G; Baldwin JJ; Taveras AG; Dwyer MP; Chao J
Bioorg Med Chem Lett; 2006 Aug; 16(15):4107-10. PubMed ID: 16697193
[TBL] [Abstract][Full Text] [Related]
13. Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat.
Garau A; Bertini R; Mosca M; Bizzarri C; Anacardio R; Triulzi S; Allegretti M; Ghezzi P; Villa P
Eur Cytokine Netw; 2006 Mar; 17(1):35-41. PubMed ID: 16613761
[TBL] [Abstract][Full Text] [Related]
14. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
Planagumà A; Domènech T; Pont M; Calama E; García-González V; López R; Aulí M; López M; Fonquerna S; Ramos I; de Alba J; Nueda A; Prats N; Segarra V; Miralpeix M; Lehner MD
Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor.
Widdowson KL; Elliott JD; Veber DF; Nie H; Rutledge MC; McCleland BW; Xiang JN; Jurewicz AJ; Hertzberg RP; Foley JJ; Griswold DE; Martin L; Lee JM; White JR; Sarau HM
J Med Chem; 2004 Mar; 47(6):1319-21. PubMed ID: 14998320
[TBL] [Abstract][Full Text] [Related]
16. Intracellular trafficking of human CXCR1 and CXCR2: regulation by receptor domains and actin-related kinases.
Matityahu E; Feniger-Barish R; Meshel T; Zaslaver A; Ben-Baruch A
Eur J Immunol; 2002 Dec; 32(12):3525-35. PubMed ID: 12442335
[TBL] [Abstract][Full Text] [Related]
17. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation.
Chapman RW; Minnicozzi M; Celly CS; Phillips JE; Kung TT; Hipkin RW; Fan X; Rindgen D; Deno G; Bond R; Gonsiorek W; Billah MM; Fine JS; Hey JA
J Pharmacol Exp Ther; 2007 Aug; 322(2):486-93. PubMed ID: 17496165
[TBL] [Abstract][Full Text] [Related]
18. LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2.
Aul R; Patel S; Summerhill S; Kilty I; Plumb J; Singh D
Int Immunopharmacol; 2012 Jul; 13(3):225-31. PubMed ID: 22561413
[TBL] [Abstract][Full Text] [Related]
19. Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2.
Nicholls DJ; Tomkinson NP; Wiley KE; Brammall A; Bowers L; Grahames C; Gaw A; Meghani P; Shelton P; Wright TJ; Mallinder PR
Mol Pharmacol; 2008 Nov; 74(5):1193-202. PubMed ID: 18676678
[TBL] [Abstract][Full Text] [Related]
20. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.
Moriconi A; Cesta MC; Cervellera MN; Aramini A; Coniglio S; Colagioia S; Beccari AR; Bizzarri C; Cavicchia MR; Locati M; Galliera E; Di Benedetto P; Vigilante P; Bertini R; Allegretti M
J Med Chem; 2007 Aug; 50(17):3984-4002. PubMed ID: 17665889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
